Research programme: in vivo CAR-T cell therapy - China Medical University Hospital/Ever Supreme Bio Technology
Alternative Names: EXO-001 - China Medical University Hospital/Ever Supreme Bio TechnologyLatest Information Update: 03 May 2026
At a glance
- Originator China Medical University Hospital; Ever Supreme Bio Technology
- Class Antineoplastics; Exosome therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 13 Feb 2026 China Medical University Hospital and Ever Supreme Bio Technology has patent protection for "Production of exosomes and uses thereof" in the US, the European Union, Taiwan, Denmark and Japan and has patent pending applications in China
- 13 Feb 2026 Preclinical trials in Solid tumours in Taiwan (IV) prior to February 2026
- 13 Feb 2026 Efficacy and adverse events data from a preclinical study in Solid tumours released by China Medical University Hospital